ASC4FIRST wk 144 analysis: Efficacy and safety and tolerability with asciminib (ASC) vs investigator-selected tyrosine kinase inhibitors (IS TKIs) in newly diagnosed (ND) chronic myeloid leukemia in chronic phase (CML-CP).
Year: 2026
Type: conference-abstract
Source: Journal of Clinical Oncology
Authors: Jorge E. Cortes, Andreas Hochhaus, Naoto Takahashi, Ghayas C. Issa, Felice Bombaci, Jianxiang Wang, Dong-Wook Kim, Dennis Dong Hwan Kim, Jiří Mayer, Yeow Tee Goh, Philipp Le Coutre, Ihno Kim, Gabriel Etienne, Kamel Malek, Tracey McCulloch, Justin Theodore Wahlstrom, Lillian Yau, Timothy P. Hughes, Richard Larson
Institutions: Augusta University, Jena University Hospital, Akita University, The University of Texas MD Anderson Cancer Center, Chinese Academy of Medical Sciences & Peking Union Medical College, Institute of Hematology & Blood Diseases Hospital, State Key Laboratory of Experimental Hematology, University Health Network, University of Toronto, Princess Margaret Cancer Centre, Eulji University Uijeongbu Eulji Medical Center, University Hospital Brno, Singapore General Hospital, Charité - Universitätsmedizin Berlin, Seoul National University, Seoul National University Hospital, Seoul National University Hospital Biomedical Research Institute, Institut Bergonié, Novartis (Switzerland), South Australian Health and Medical Research Institute, The University of Adelaide, University of Chicago
Language: English
Subfield: Hematology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W7162544940
Cites:
Cited by:
Related to: